Fluoroquinolones are a class of broad-spectrum antibiotics used to treat serious bacterial infections, including pneumonia, urinary tract infections, and certain skin and bone infections. They are among the most widely prescribed antibiotics in the world, with ciprofloxacin (Cipro) and levofloxacin (Levaquin) being the most recognizable names. Despite their effectiveness, fluoroquinolones carry significant safety warnings that have led both the FDA and the European Medicines Agency to restrict their use to situations where safer alternatives aren’t available.
How Fluoroquinolones Kill Bacteria
Bacteria rely on two essential enzymes, DNA gyrase and topoisomerase IV, to copy and maintain their DNA. These enzymes work by temporarily cutting both strands of the DNA double helix, passing another strand through the gap, and then resealing the break. Fluoroquinolones interfere with the resealing step. The drug locks onto the enzyme while it’s bound to the broken DNA, creating a stable but toxic complex that blocks the cell’s ability to replicate its genetic material.
This does more than just stall DNA replication. The trapped enzyme-DNA complexes act as roadblocks for other cellular machinery, and the unrepaired double-strand breaks are lethal to the bacterium. This is why fluoroquinolones are classified as bactericidal, meaning they actively kill bacteria rather than simply slowing their growth.
Four Generations of Fluoroquinolones
The class has evolved through four generations, each broadening the range of bacteria the drugs can target.
- First generation: Nalidixic acid, the original quinolone from the 1960s, was effective only against certain gut and urinary tract bacteria. It’s rarely used today.
- Second generation: This is where the “fluoro” was added to the chemical structure, dramatically improving potency. Ciprofloxacin, norfloxacin, ofloxacin, and levofloxacin all belong here. These drugs have strong activity against gram-negative bacteria (like E. coli and Pseudomonas) and moderate activity against some gram-positive species.
- Third generation: Drugs like gatifloxacin and sparfloxacin expanded coverage to include more gram-positive bacteria, though several were later withdrawn due to safety concerns.
- Fourth generation: Moxifloxacin (Avelox) and gemifloxacin added even broader gram-positive coverage, including better activity against bacteria that cause respiratory infections. These are sometimes called “respiratory fluoroquinolones.”
In practice, most prescriptions today involve ciprofloxacin, levofloxacin, or moxifloxacin. Many earlier drugs in the class were pulled from the market after serious side effects emerged.
What They’re Prescribed For
Fluoroquinolones are typically reserved for infections that are difficult to treat with safer antibiotics. Their most common uses include complicated urinary tract infections, bacterial pneumonia (especially hospital-acquired cases), chronic bronchitis flare-ups when first-line antibiotics have failed, and certain gastrointestinal infections.
For community-acquired pneumonia, guidelines vary by country. In the United States, the CDC has recommended that fluoroquinolones not be used routinely for pneumonia and should be reserved for patients who have failed other treatments or who have drug-resistant bacteria. Canadian guidelines take a different approach, listing respiratory fluoroquinolones as a first choice for hospitalized pneumonia patients. For hospital-acquired pneumonia, ciprofloxacin or levofloxacin is often used as part of a combination regimen, particularly when drug-resistant organisms are suspected.
Fluoroquinolones are not appropriate for mild infections. Regulatory agencies in the U.S. and Europe have explicitly stated these drugs should not be used for sore throats, uncomplicated sinus infections, uncomplicated urinary tract infections, prevention of traveler’s diarrhea, or non-bacterial conditions like chronic prostatitis.
How They Move Through Your Body
One reason fluoroquinolones became so popular is their excellent oral absorption. Most drugs in the class achieve near-complete bioavailability when taken by mouth, meaning a pill delivers nearly as much drug to your bloodstream as an IV would. They also distribute widely into tissues, reaching high concentrations in the lungs, prostate, and bone, which makes them useful for infections in hard-to-reach areas.
Elimination varies by drug. Levofloxacin and ofloxacin are cleared almost entirely by the kidneys, with 70 to 80 percent excreted unchanged in urine. Ciprofloxacin follows a mixed route, with 30 to 45 percent leaving through the kidneys and the rest broken down by the liver. Half-lives range from about 3 to 5 hours for ciprofloxacin to 8 to 14 hours for longer-acting drugs, which is why some fluoroquinolones are dosed once daily and others twice.
Serious Side Effects and FDA Warnings
Fluoroquinolones carry an FDA boxed warning, the strongest safety label the agency issues. The warning covers multiple side effects that can be disabling and, in some cases, permanent. These include tendon inflammation and rupture, peripheral neuropathy (pain, burning, tingling, or numbness in the hands and feet), and central nervous system effects such as confusion, dizziness, and mood changes. Muscle pain, muscle weakness, and joint swelling are also listed.
The risk of tendon problems is relatively low in the general population, occurring in roughly 0.14 to 0.4 percent of users, but certain groups face substantially higher odds. Adults over 60 are at 1.5 times greater risk of tendon disorders and 2.7 times greater risk of tendon rupture compared to younger patients. Corticosteroid use, kidney disease, and dialysis further increase the risk. When tendon injuries do occur, the Achilles tendon is the most commonly affected site, with about 27 percent of cases involving both legs. The average age of someone who develops fluoroquinolone-related tendon damage is 64, and men are affected twice as often as women.
The FDA has also warned that fluoroquinolones are associated with ruptures or tears of the aorta, the body’s largest blood vessel. People with a history of aneurysms, high blood pressure, hardened arteries, or genetic connective tissue disorders like Marfan syndrome or Ehlers-Danlos syndrome face the highest risk. Elderly patients are also more vulnerable. For these groups, fluoroquinolones should only be used when no other antibiotic will work.
Both the FDA and the European Medicines Agency advise stopping fluoroquinolone treatment at the first sign of tendon pain, joint swelling, or nerve symptoms like tingling or numbness. Early discontinuation may prevent these effects from becoming permanent.
How Bacteria Become Resistant
Widespread fluoroquinolone use has predictably led to growing bacterial resistance. The primary mechanism involves spontaneous mutations in the genes encoding DNA gyrase and topoisomerase IV, the very enzymes the drugs target. These mutations alter the enzyme’s shape just enough that the drug can no longer bind effectively. Resistant bacteria exist naturally at low frequencies, roughly one in every million to one billion cells, but antibiotic exposure kills off the susceptible majority and allows resistant strains to dominate.
A second resistance mechanism involves changes in how bacteria regulate their outer membranes. Some resistant strains reduce the number of channels that allow the drug to enter the cell, while others ramp up efflux pumps that actively push the drug back out before it can reach its target. Unlike some other antibiotic classes, no bacteria have been found that produce enzymes capable of breaking down or chemically inactivating fluoroquinolones. Resistance is entirely about keeping the drug away from its target or changing the target itself.
Who Should Avoid Fluoroquinolones
Beyond the general population risks, several specific groups should avoid fluoroquinolones whenever possible. People who have experienced serious side effects from a previous fluoroquinolone or quinolone course should generally not take them again. Those with connective tissue disorders, a history of aortic aneurysm, peripheral vascular disease, or uncontrolled high blood pressure face elevated cardiovascular risks. People with myasthenia gravis, a neuromuscular condition, may experience dangerous worsening of muscle weakness.
For older adults, particularly those also taking corticosteroids, the combination of tendon, nerve, and vascular risks makes fluoroquinolones a last-resort option. The consistent message from regulatory agencies is straightforward: these are powerful antibiotics that work well for serious infections, but their risk profile means they should not be prescribed when a safer alternative exists.